DFTX — Definium Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Definium Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -93 | -56.8 | -95.7 | -109 | -184 |
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 42.7 | 7.08 | 22 | 32.4 | 42.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.04 | -3.6 | 6.23 | -3.39 | 9.41 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -45.8 | -50.1 | -64.4 | -79.1 | -132 |
| Other Investing Cash Flow Items | -0.297 | 0 | — | — | -152 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.297 | 0 | — | — | -152 |
| Financing Cash Flow Items | 0 | -0.407 | 0 | 0.431 | 242 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 98.8 | 59.1 | 21.8 | 253 | 267 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 53.4 | 8.6 | -42.4 | 174 | -15.9 |